NEW YORK (GenomeWeb News) — French molecular diagnostics company IntegraGen said today it has appointed Bernard Courtieu as CEO to help the firm “accelerate its commercial efforts.”
“We are on the brink of emerging from a research and services firm … to a company able to quickly deliver innovative products though our pipeline and fuel further discovery,” Courtieu said.
The company, which focuses on diseases such as obesity, autism, diabetes, schizophrenia, and bipolar disorder, is based in Paris and formed a US subsidiary in New York in December 2006. That business is headed by former Roche executive Robert Gottlieb.
Courtieu was a vice president at Gemini Consulting, and he has worked as a consultant for a variety of firms. IntegraGen said Courtieu has experience in R&D, industrial operations, supply-chain management, sales and marketing, and information systems.